Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
  2. >
  3. Stock
  4. >
  5. ITRM
stocks logo

ITRM

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.090
-64%
--
--
-0.100
-28.57%
--
--
-0.100
-37.5%
Estimates Revision
The market is revising No Change the revenue expectations for Iterum Therapeutics plc (ITRM) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -35.12%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Down
down Image
-35.12%
In Past 3 Month
Wall Street analysts forecast ITRM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ITRM is 2.00 USD with a low forecast of 2.00 USD and a high forecast of 2.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast ITRM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ITRM is 2.00 USD with a low forecast of 2.00 USD and a high forecast of 2.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.440
sliders
Low
2.00
Averages
2.00
High
2.00
Current: 0.440
sliders
Low
2.00
Averages
2.00
High
2.00
H.C. Wainwright
H.C. Wainwright
initiated
$9
2025-05-08
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$9
2025-05-08
initiated
Reason
H.C. Wainwright assumed coverage of Iterum Therapeutics with a Buy rating and $9 price target. Iterum is a pre-commercial stage company with an FDA approved product, the analyst tells investors in a research note. The firm says the company has the potential to deliver in urinary tract infections and infectious disease.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Iterum Therapeutics PLC (ITRM.O) is -1.16, compared to its 5-year average forward P/E of -2.16. For a more detailed relative valuation and DCF analysis to assess Iterum Therapeutics PLC 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-2.16
Current PE
-1.16
Overvalued PE
0.26
Undervalued PE
-4.58

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.79
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.28
Undervalued EV/EBITDA
-2.87

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
393.32
Current PS
0.00
Overvalued PS
2102.57
Undervalued PS
-1315.93
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Financial AI Agent
Financial AI Agent

ITRM News & Events

Events Timeline

(ET)
2025-11-24
08:09:52
Iterum Therapeutics Secures 510(k) Approval for Susceptibility Test Disc
select
2025-11-14 (ET)
2025-11-14
07:06:00
Iterum Therapeutics projects funding to last until the second quarter of 2026.
select
2025-11-14
07:04:48
Iterum Therapeutics Announces Q3 Non-GAAP EPS of 16 Cents Compared to 24 Cents Last Year
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
5.0
11-24NASDAQ.COM
Butterfly Network and Citius Pharma Boost Biotech Activity in After-Hours Trading
  • Butterfly Network Update: Butterfly Network's shares rose 6.04% after announcing CEO Joseph DeVivo and Interim CFO Megan Carlson will participate in investor meetings at the Evercore Healthcare Conference on December 2, 2025, highlighting their handheld ultrasound technology.

  • Citius Pharmaceuticals Collaboration: Citius Pharmaceuticals saw a 7.90% increase in shares after announcing a collaboration with Verix to utilize its AI-powered Tovana platform for the U.S. commercialization of LYMPHIR, an FDA-approved immunotherapy for cutaneous T-cell lymphoma.

  • General Market Activity: ProQR Therapeutics, Perrigo Company, and Tempest Therapeutics also experienced share price increases, with Tempest announcing plans to acquire CAR-T programs to enhance its pipeline.

  • Other Stocks Performance: Iterum Therapeutics and Processa Pharmaceuticals had minor share price movements without any new updates, reflecting varied investor sentiment in the biotech sector.

[object Object]
Preview
9.5
11-14NASDAQ.COM
Applied Therapeutics, Omeros, and Others Experience Significant Price Changes After Market Close
  • Milestone Scientific Inc. Earnings: Milestone Scientific's shares rose 36.10% after reporting a third-quarter net loss of $1.2 million, with revenue slightly down to $2.4 million due to weaker domestic dental sales but stronger international demand.

  • Applied Therapeutics Inc. Update: Applied Therapeutics saw a 14.78% increase in shares after narrowing its Q3 net loss to $19 million and announcing a meeting with the FDA to discuss the regulatory path for govorestat in Classic Galactosemia.

  • Omeros Corp. Financial Results: Omeros Corp. shares gained 20.54% following a Q3 net loss of $30.9 million, with an update on its Biologics License Application for narsoplimab and an extended FDA action date to December 2025.

  • The Oncology Institute Inc. Performance: The Oncology Institute's shares rose 19.48% after reporting a 36.7% increase in Q3 revenue to $136.6 million, while also raising its full-year revenue guidance to between $495 million and $505 million.

[object Object]
Preview
3.0
11-14NASDAQ.COM
Earnings Report Ahead of Market Opening for November 14, 2025: SR, SRRK, TWST, BTBT, SGML, FRGE, SBC, GAUZ, INKT, MRSN, ITRM, LMFA
  • Earnings Reports Overview: Several companies, including Spire Inc., Scholar Rock Holding Corporation, and Twist Bioscience Corporation, are set to report their earnings for the quarter ending September 30, 2025, with varying forecasts for earnings per share (EPS) and growth compared to the previous year.

  • Spire Inc. Performance: Spire Inc. is expected to report an EPS of $-0.46, reflecting a 14.81% increase year-over-year, with a Price to Earnings (P/E) ratio of 20.08, indicating stronger growth potential than its industry peers.

  • Scholar Rock Holding Corporation and Twist Bioscience: Scholar Rock is forecasted to have an EPS of $-0.88, a 33.33% decrease from last year, while Twist Bioscience anticipates an EPS of $-0.40, a 32.20% increase, despite missing previous earnings expectations.

  • Other Notable Companies: Companies like Bit Digital, Sigma Lithium, and SBC Medical Group are also reporting, with SBC Medical expected to show significant growth with a 333.33% increase in EPS, while others like MiNK Therapeutics and Mersana Therapeutics are facing declines in their EPS forecasts.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Iterum Therapeutics PLC (ITRM) stock price today?

The current price of ITRM is 0.44 USD — it has increased 5.51 % in the last trading day.

arrow icon

What is Iterum Therapeutics PLC (ITRM)'s business?

Iterum Therapeutics plc is a clinical-stage pharmaceutical company. The Company develops differentiated anti-infectives. It offers ORLYNVAH (sulopenem in an oral tablet formulation) medicine, which is an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by the designated microorganisms Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis in adult women. Sulopenem is a potent, thiopenem antibiotic delivered intravenously which is active against bacteria that belong to the group of organisms known as gram-negatives and cause urinary tract and intra-abdominal infections. The Company operates as a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.

arrow icon

What is the price predicton of ITRM Stock?

Wall Street analysts forecast ITRM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ITRM is 2.00 USD with a low forecast of 2.00 USD and a high forecast of 2.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Iterum Therapeutics PLC (ITRM)'s revenue for the last quarter?

Iterum Therapeutics PLC revenue for the last quarter amounts to 390.00K USD, decreased % YoY.

arrow icon

What is Iterum Therapeutics PLC (ITRM)'s earnings per share (EPS) for the last quarter?

Iterum Therapeutics PLC. EPS for the last quarter amounts to -0.20 USD, decreased -33.33 % YoY.

arrow icon

What changes have occurred in the market's expectations for Iterum Therapeutics PLC (ITRM)'s fundamentals?

The market is revising No Change the revenue expectations for Iterum Therapeutics plc (ITRM) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -35.12%.
arrow icon

How many employees does Iterum Therapeutics PLC (ITRM). have?

Iterum Therapeutics PLC (ITRM) has 9 emplpoyees as of December 05 2025.

arrow icon

What is Iterum Therapeutics PLC (ITRM) market cap?

Today ITRM has the market capitalization of 23.23M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free